---
category: news
title: "CRISPR (CRSP) to Begin Clinical Study on Diabetes Therapy Drug"
excerpt: "CRISPR Therapeutics CRSP, along with partner ViaCyte, announced that Health Canada has approved the clinical trial application for its investigational allogeneic stem cell-derived therapy, VCTX210. The candidate will be evaluated as a potential treatment for type 1 diabetes (T1D)."
publishedDateTime: 2021-11-17T14:45:00Z
originalUrl: "https://www.nasdaq.com/articles/crispr-crsp-to-begin-clinical-study-on-diabetes-therapy-drug"
webUrl: "https://www.nasdaq.com/articles/crispr-crsp-to-begin-clinical-study-on-diabetes-therapy-drug"
ampWebUrl: "https://www.nasdaq.com/articles/crispr-crsp-to-begin-clinical-study-on-diabetes-therapy-drug?amp"
cdnAmpWebUrl: "https://www-nasdaq-com.cdn.ampproject.org/c/s/www.nasdaq.com/articles/crispr-crsp-to-begin-clinical-study-on-diabetes-therapy-drug?amp"
type: article

provider:
  name: Nasdaq
  domain: nasdaq.com

topics:
  - AI in Healthcare
  - AI

secured: "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;pjsQaglnTnlbZI/YUQFTKQ=="
---

